Safety and Efficacy of Anricfen for Postoperative Analgesia and Rehabilitation Promotion After Pancreaticoduodenectomy.Intervention Measures: For Normal Adults, Administer Ariceptin Injection Intravenously Post-operation at a Dose of 1 μg/Kgevery 8 Hours for Three Consecutive Days After Surgery.

NCT07514637 · tracked via the Priya Life Science China tracker

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase

Phase 2

Started

2025-11-25

Last updated

2026-04-07

Condition(s) studied

Patients Who Undergo Pancreaticoduodenectomy

Investigational drug(s) / intervention(s)

Experimental GroupAnrikefon →

Experimental Group: Postoperatively, administer Anrikefon injection intravenously at a dose of 1 μg/kg every 8 hours for three consecutive days.

Anrikefon: Postoperatively, intravenous injection of Anrikefon injection was administered at a dose of 1 μg/kg, every 8 hours, for three consecutive days as an intervention

Study summary

Exploring the effectiveness and safety of early use of Ariceptinfen after pancreaticoduodenectomy in alleviating postoperative pain and promoting recovery of patients.

Main objective: To explore the analgesic effect of Anricfen after pancreaticoduodenectomy.

Secondary objective: To explore the impact of Anricfen on the accelerated recovery after pancreaticoduodenectomy.

Exploratory objective: To investigate the biomarkers of Anricfen's analgesic effect after pancreaticoduodenectomy, as well as its correlation factors with tumor pathology.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: * Patients who underwent pancreatic surgery, including pancreaticoduodenectomy (PD), pancreatic-preserving pancreaticoduodenectomy (PPPD), and laparoscopic pancreaticoduodenectomy (LPD) * Age ≥ 18 years old and \< 80 years old * ASA Ⅰ-Ⅲ * Be able to clearly understand and voluntarily participate in the research Exclusion Criteria: * Merging severe primary diseases involving the heart, brain, liver, kidneys and hematopoietic system * History of long-term use of psychotropic drugs and cognitive dysfunction * Having a history of acute poisoning from alcohol, sleeping pills, painkillers or other drugs that affect the central nervous system * Pregnancy or lactation period * History of allergy to NSAIDs, opioids, or to the test medication * Drug users, alcoholics, and opiate abusers * Those who had a history of chronic pain before the operation and a history of long-term use of analgesics and/or sedatives * Those who had thyroid dysfunction before the operation

Primary outcome measure(s)

The incidence of postoperative complications — After undergoing treatment for 2 months
Incidence rate of adverse events — Two month after the treatment
The VAS score within 0-72 hours after the operation — Within 3 days after receiving treatment

Trial sites (1)

Facility	City	Region	Status
NanJing drum tower hospital	Nanjing	China	Recruiting

More The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials in China

Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy Recruiting

Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus Recruiting

CHT105 for the Treatment of Refractory Lupus Nephritis Enrolling by invitation

Clinical Classification and Imaging Markers in Patients of Obesity Enrolling by invitation

A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07514637 on ClinicalTrials.gov ↗ ← All trials in China